non-motor aspects of parkinson’s disease a psychiatrist’s perspective
DESCRIPTION
Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective. Geriatrics Day 2009 Ronald Bailyn , M.D. Cognitive impairment/Dementia Psychosis Depression Apathy Anxiety Fatigue Sleep Disturbance. Non-Motor Symptoms. Dopamine/serotonin. Neurotransmitters-pathways. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/1.jpg)
Non-motor Aspects of Non-motor Aspects of Parkinson’s DiseaseParkinson’s Disease
a Psychiatrist’s a Psychiatrist’s PerspectivePerspective
Geriatrics Day 2009
Ronald Bailyn, M.D.
![Page 2: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/2.jpg)
Non-Motor SymptomsNon-Motor Symptoms
Cognitive impairment/Dementia
Psychosis
Depression
Apathy
Anxiety
Fatigue
Sleep Disturbance
![Page 3: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/3.jpg)
Neurotransmitters-pathwaysNeurotransmitters-pathways
Dopamine/serotonin
![Page 4: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/4.jpg)
Deep Brain Stimulation Deep Brain Stimulation
Deep Brain Stimulation – Affective Events
depression (up to 25%) J Neurol Neurosurg Psychiatry
2008;79:952-954 hypomania
agitation
apathy
![Page 5: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/5.jpg)
DepressionDepression
![Page 6: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/6.jpg)
DepressionDepression
Depression Prevalence in Parkinson’s Disease
Depression -- major and minor
o ~ 5-10% major depressiono ~ 20-30% minor depression
![Page 7: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/7.jpg)
DepressionDepression
Depression
Depression is associated with reduced cognition, faster progression of physical symptoms and decreased treatment adherence
Retrospective studies suggest higher incidence as long as 20 years before diagnosis
Some indication of greater depression risk with early onset, for women and with right predominant
motor symptoms
![Page 8: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/8.jpg)
Depression in ParkinsonsDepression in Parkinsons
From Daniel Weintraub, M.D.University of Pennsylvania
![Page 9: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/9.jpg)
Depression TreatmentDepression Treatment
Serotonin, norepinephrine and dopaminergic neurotransmitter changes in Parkinson’s provide
a theories for treatment, but little clinical research to guide treatment
Limited evidence for specific medications (3 trials -- Cochrane 2007)
o Substantial use of SSRIs (Zoloft, Prozac, Celexa/Lexapro) possibility of aggravating motor sx
o Nortriptyline (tricyclic – has best data)
o ECT
![Page 10: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/10.jpg)
Nortriptyline &Nortriptyline &Paroxetine StudyParoxetine Study
Menza M, Dobkin RD et al: Neurology 2008; (online Ahead of Print Dec. 17, 2008)
Trial Design:
Nortriptyline 25, 50, 75 mg Paroxetine CR 12.5, 25, 37.5 mg Placebo 1, 2, 3 pills
8 week randomized, double blind, Ham D Assessed 2, 4 and 8 weeks 52 patients Age 35-80 (mean 62)
![Page 11: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/11.jpg)
Nortriptyline &Nortriptyline &Paroxetine StudyParoxetine Study
Results
Nortriptyline › placebo (0.002) Nortriptyline › paroxetine N.S. (0.08)
Response (= 50% improvement Ham D) 53% nortriptyline 11% paroxetine
24% placebo
Remission (= Ham D of 7 or less) 41% nortriptyline 17% paroxetine 12 % placebo
![Page 12: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/12.jpg)
Depression &Depression &PsychotherapyPsychotherapy
Cognitive Behavioral Therapy (CBT)
Supported in limited trials/clinical experience
![Page 13: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/13.jpg)
Antidepressant Choices Antidepressant Choices
Class Med Avg dose(mg/day)
Start Comments
SSRI EcitalopramParoxetineSertraline
10 2050-100
101025
Also used for anxiety – often at higher doses.Can worsen motor Sx.
SNRI VenlafaxineDuloxetine
37.5 – 15020-30
37.520-30
Useful for anxiety and depression
TCA Nortriptyline 50-150 25 Blood levels can be helpful.Usually night dosing.
Other BupropionMirtazapine
100-30015-45
10015
Bupropion can be activatingMirtazapine can be sedating – usually night dosing
Adapted from: Dialogues inClinical Neuroscience – Parkinson’sDisease; 2004: Vol. 6 No. 3 p324
![Page 14: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/14.jpg)
AnxietyAnxiety
![Page 15: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/15.jpg)
Anxiety Disorders Anxiety Disorders
Anxiety
20-30% frequency of anxiety disorders
General anxiety, panic attacks, obsessive-compulsive
problems can present in Parkinson’s Disease
Impulse control disorders (gambling, sex, buying)o dopamine agonist association o ~ 4% prevalence (Weintraub)
![Page 16: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/16.jpg)
Anxiety Disorder Anxiety Disorder TreatmentTreatment
Anxiety Treatment
Very little study or even case report literature
o Significant use of SSRIs and other antidepressant medications
o Low dose benzodiazepine medications (lorazepam, clonazepam)
(monitor sedation & balance)
o Cognitive Behavioral Treatment
![Page 17: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/17.jpg)
ApathyApathy
![Page 18: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/18.jpg)
ApathyApathy
Apathy
10-20% frequency – loss of goal directed behavior, life interest
Little treatment information – trials of norepinephrine and dopaminergic agents Wellbutrin, stimulants (ex. Ritalin, Strattera) Education (family) Environmental stimulation
![Page 19: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/19.jpg)
SleepSleep
![Page 20: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/20.jpg)
Sleep disordersSleep disorders& Treatment& Treatment
Various and frequent sleep disorders
Insomnia o sleep behavioral efforts o sleep medications (Tandberg 1999 study ~ 40% pts taking)
Parkinson’s motor symptomso night dose Sinemet CR
Restless legs o dopaminergic medications
![Page 21: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/21.jpg)
Sleep disordersSleep disorders& Treatment& Treatment
More sleep disorders
REM behavior disorder o benzodiazepine (clonazepam)
Excessive daytime sleepiness (EDS)o thought to be direct symptom of Parkinson’s o review effects of Parkinson’s medicationso Provigil study negative
![Page 22: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/22.jpg)
Behavioral/cognitive approaches to depression and Behavioral/cognitive approaches to depression and sleep problemssleep problems
![Page 23: Non-motor Aspects of Parkinson’s Disease a Psychiatrist’s Perspective](https://reader035.vdocuments.us/reader035/viewer/2022062408/56812fef550346895d95665e/html5/thumbnails/23.jpg)
endend